AceMab of Taichu Group Honored with National Invention Patent Authorization

AceMab, a JV company of Taichu Group, has been granted authorization by the China National Intellectual Property Administration (CNIPA) for its invention patent titled "Recombinant Genome, Non-Human Mammalian Cells and Methods and Uses for Their Production".

AceMab's AceMouse™ Fully Humanized Antibody Mouse Platform Facilitates Medical Breakthroughs, Leading a New Era in Antibody Discovery!

The AceMouse™ series of mouse platforms is AceMab's core technology platform for the rapid and efficient development of fully human antibody drugs. Antibodies developed using this platform exhibit rich diversity, low immunogenicity, high affinity, and good developability, representing the optimal route for current antibody drug development. AceMouse™ facilitates medical breakthroughs and leads a new era in antibody discovery!

The AceMouse™ series includes:

l    AceMouse™: Fully humanized mice for antibody heavy and light chains.

l    AceMouseCL™: Fully humanized mice with a common light chain.

l    AceMouseNB™: Fully humanized mice for heavy chain only (Nanobody) antibodies.

This platform enables the development of fully human monoclonal antibodies, bispecific antibodies, multispecific antibodies, nanobodies, single-chain antibodies, etc. It significantly reduces risks and costs in subsequent antibody drug development and shortens the antibody drug R&D cycle.

Leveraging the AceMouse™ series platform, AceMab has already developed and delivered over 20 types of fully human antibodies targeting different antigens and application formats for its partners, receiving widespread acclaim within the industry.